UBS Group reissued their neutral rating on shares of GlaxoSmithKline (LON:GSK) in a research report report published on Friday morning, ThisIsMoney.Co.Uk reports.
GSK has been the subject of several other reports. Credit Suisse Group assumed coverage on Regeneron Pharmaceuticals in a research note on Monday, May 20th. They set a neutral rating and a $336.00 target price for the company. Kepler Capital Markets raised their target price on GlaxoSmithKline from GBX 1,440 ($18.82) to GBX 1,540 ($20.12) and gave the company a hold rating in a research note on Tuesday, June 11th. Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the company a buy rating in a research note on Monday, July 15th. Deutsche Bank restated a buy rating and set a $80.00 target price on shares of Bayerische Motoren Werke in a research note on Monday, July 8th. Finally, Jefferies Financial Group restated a buy rating and set a C$15.00 target price on shares of Aphria in a research note on Friday, May 24th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and five have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of GBX 1,536.87 ($20.08).
Shares of GlaxoSmithKline stock opened at GBX 1,654.60 ($21.62) on Friday. The firm’s 50-day simple moving average is GBX 1,603.27. The company has a quick ratio of 0.45, a current ratio of 0.72 and a debt-to-equity ratio of 942.07. The firm has a market capitalization of $82.53 billion and a P/E ratio of 21.08. GlaxoSmithKline has a 1-year low of GBX 1,408.80 ($18.41) and a 1-year high of GBX 1,658 ($21.66).
In other news, insider Manvinder Singh Banga purchased 458 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was acquired at an average cost of GBX 1,568 ($20.49) per share, for a total transaction of £7,181.44 ($9,383.82). Insiders purchased 482 shares of company stock valued at $755,935 over the last quarter.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Read More: How to interpret the current ratio
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.